Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | NOTCH1 act mut |
Therapy | Dexamethasone + Ribociclib |
Indication/Tumor Type | T-cell adult acute lymphocytic leukemia |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NOTCH1 act mut | T-cell adult acute lymphocytic leukemia | predicted - sensitive | Dexamethasone + Ribociclib | Preclinical - Pdx | Actionable | In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) resulted in reduced leukemia burden and a greater survival benefit in a NOTCH1 activated T-cell acute lymphoblastic leukemia patient derived xenograft (PDX) model when compared to control or either agent alone (PMID: 28151717). | 28151717 |
PubMed Id | Reference Title | Details |
---|---|---|
(28151717) | Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. | Full reference... |